Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
0.6005
-0.0196 (-3.16%)
Streaming Delayed Price
Updated: 10:31 AM EDT, May 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Via
ACCESS Newswire
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 07, 2026
Via
ACCESS Newswire
Lexaria Updates Progress on Human Study #7
May 05, 2026
Via
ACCESS Newswire
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 01, 2026
Via
ACCESS Newswire
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026
Via
ACCESS Newswire
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026
Via
ACCESS Newswire
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026
Via
ACCESS Newswire
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
April 15, 2026
Via
ACCESS Newswire
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
Via
ACCESS Newswire
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects
Via
TheNewswire.com
Lexaria to Begin New Human Clinical Study in GLP-1
April 01, 2026
Via
ACCESS Newswire
Lexaria's Robust Patent Portfolio Continues to Grow
March 26, 2026
Via
ACCESS Newswire
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
March 24, 2026
Via
ACCESS Newswire
Lexaria Announces New R&D Plans for 2026
March 04, 2026
Via
ACCESS Newswire
Lexaria Announces Positive Final Results From Human Pilot Study #5
February 05, 2026
Via
ACCESS Newswire
Lexaria Awarded Six Additional Patents
January 22, 2026
Lexaria now has 60 patents granted around much of the world
Via
TheNewswire.com
Topics
Intellectual Property
Lexaria Awarded Six Additional Patents
January 22, 2026
Via
ACCESS Newswire
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
January 21, 2026
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.
From
USA News Group
Via
GlobeNewswire
Lexaria Releases Annual Letter from the CEO
January 12, 2026
Via
ACCESS Newswire
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
December 30, 2025
Via
ACCESS Newswire
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
December 23, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
Via
ACCESS Newswire
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
November 12, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Provides Strategic Update
October 09, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 29, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 26, 2025
Via
ACCESS Newswire
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
September 19, 2025
Via
ACCESS Newswire
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
August 27, 2025
Via
ACCESS Newswire
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
August 14, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
